This content is machine translated Acute myeloid leukemia (AML) “A new standard of care for elderly and fragile patients” A BCL-2 inhibitor is convincing in new studies in the first-line treatment of AML patients who are not suitable for intensive chemotherapy [1]. Hematologists Dr. Georgios Georgiou and Prof. Photis…
View Post 7 min This content is machine translated TRK Inhibitors Entity-independent cancer therapy: a glimpse of the future? Since 2020, two TRK inhibitors have been approved in Switzerland for tumor diagnosis, i.e. independent of tumor entity. They are designed to treat any solid tumor with NTRK gene fusions,…
View Post 4 min This content is machine translated Non-small cell lung cancer The role of adjuvant EGFR TKIs. Over the past several years, tyrosine kinase inhibitors directed against EGFR have gained acceptance as first-line treatment for advanced NSCLC with EGFR mutation. However, their role in adjuvant therapy of…
View Post 7 min This content is machine translated Renal cell carcinoma The most important studies at a glance Some exciting studies were presented on renal cell carcinoma at this year’s ASCO annual meeting. Especially for localized tumors, clinical practice may change in the near future. For the first…
View Post 4 min This content is machine translated Actinic keratoses Topical treatment options – an update Actinic keratoses are the most common dermatoses on chronically sun-damaged skin, especially in people with fair skin types. Prevalence increases significantly from the sixth decade of life. The spectrum of lesion-targeted…
View Post 8 min This content is machine translated Surgical techniques Dermatosurgery of skin tumors for practice In view of the massive increase in skin cancer, dermatosurgery is also gaining in importance. Many skin cancer patients can be diagnosed and treated with biopsies and excisions in the… CME-Test
View Post 6 min This content is machine translated Metastatic colorectal carcinoma A challenging opponent With a median survival of about two years, the prognosis for metastatic colorectal cancer remains poor. New therapeutic options have brought some improvement in recent years, but major breakthroughs have…
View Post 7 min This content is machine translated Lung tumors What’s new? Among the approximately 200 abstracts on thoracic oncology at this year’s ASCO Annual Meeting , exciting news was found especially on non-small cell lung cancer (NSCLC). With immunotherapeutic options in…
View Post 4 min This content is machine translated Non-resectable BRAF-mutated melanoma 5-year data from COLUMBUS study support continued long-term benefits After five years of follow-up in the COLUMBUS study, it is clear that patients with non-resectable or metastatic melanoma with a BRAFV600 mutation benefit long-term from encorafenib in combination with…
View Post 5 min This content is machine translated Multiple Myeloma Focus on first-line therapy The innovation of recent years has long since found its way into first-line therapy in multiple myeloma. Thus, the EHA-ESMO Guidelines were amended accordingly in January. Daratumumab, a monoclonal antibody…
View Post 5 min This content is machine translated Adjuvant melanoma treatment Interim analysis of “real world” data from the DACH region For the majority of melanoma patients, much more effective therapies are available today than a few years ago. This also applies to adjuvant melanoma treatment. Many new therapeutic approaches have…
